Urolithin A vs Fisetin: How They Compare

Urolithin A and fisetin both show up in longevity conversations, but they work on entirely different parts of the cell. One renews your mitochondria; the other targets aged, lingering cells. Understanding that split makes it much easier to decide which belongs in your routine.

Two compounds, two very different jobs

It is easy to lump urolithin A and fisetin together because both are plant-derived polyphenols marketed for healthy aging. But they are not interchangeable, and they do not compete for the same mechanism. Urolithin A is a gut postbiotic — your microbiome makes it from ellagitannins found in pomegranates, walnuts, and berries. Its signature action is mitophagy: the cell's process for identifying worn-out mitochondria and recycling them so newer, more efficient ones can take their place. Fisetin is a flavonoid found in strawberries, apples, persimmons, and onions, and its most-studied role is as a senolytic — a compound that helps clear senescent cells, sometimes called 'zombie' cells, that stop dividing but linger and release inflammatory signals.

In short: urolithin A is about the quality of the power plants inside your cells, while fisetin is about the population of aged cells in a tissue. Neither replaces the other, and comparing them head-to-head only makes sense once you know what each is actually trying to do.

Mechanism, side by side

Urolithin A: mitochondrial renewal

Mitochondria generate most of the energy your cells use, but they wear down over time. When damaged mitochondria accumulate faster than they are cleared, cellular energy output tends to fall. Urolithin A supports mitophagy, the targeted recycling of those damaged mitochondria, which in turn supports the cell's capacity to maintain a healthier mitochondrial pool. A practical wrinkle worth knowing: not everyone's gut microbiome converts dietary ellagitannins into urolithin A efficiently, which is one reason a standardized supplemental dose can matter more than simply eating more pomegranate.

Fisetin: clearing senescent cells and calming inflammation

As tissues age, some cells enter senescence — they stop dividing but resist normal turnover and secrete a mix of inflammatory molecules known as the senescence-associated secretory phenotype. Fisetin is studied as a senolytic that may help the body clear a portion of these cells, and it also has well-documented antioxidant and anti-inflammatory activity in laboratory settings. The two mechanisms are complementary in theory: mitophagy tidies the inside of a working cell, while senolytics reduce the burden of cells that have effectively stopped working.

The evidence for urolithin A, organized by strength

Urolithin A is unusual in this category because it has a growing base of human randomized data, not just animal work. We think it is important to separate what has been shown in people from what has only been shown in cells or animals.

Human trials (strongest evidence)

The first-in-human study, Andreux and colleagues in Nature Metabolism (2019), found urolithin A was safe and well tolerated at doses up to 1,000 mg per day and produced a mitochondrial gene-expression signature in participants. Liu, D'Amico and colleagues published in JAMA Network Open (2022) a roughly four-month trial in older adults showing improved muscle endurance, measured as the number of muscle contractions before fatigue. Singh and colleagues in Cell Reports Medicine (2022) studied middle-aged adults over four months across 500 mg and 1,000 mg arms and reported benefits to muscle strength and exercise performance. A 2025 Nature Aging randomized trial over about 28 days found urolithin A supported immune-cell mitochondrial health in midlife adults, relevant to age-related inflammation. A 2024 Journal of the International Society of Sports Nutrition eight-week trial in resistance-trained men reported effects on endurance and recovery markers, and a 2025 distance-runners trial added further exercise data.

What the reviews say

A 2024 systematic review in Ageing Research Reviews, 'Targeting aging with urolithin A in humans,' is candid that the human evidence is still emerging: trials so far are relatively short and modest in size. That honesty is worth carrying with you — the human signal is real and consistent for muscle and mitochondrial endpoints, but it is early.

Preclinical foundation (animal and cell, not human proof)

The foundational work by Ryu and colleagues in Nature Medicine (2016) demonstrated that urolithin A induced mitophagy, extended lifespan in C. elegans, and improved muscle function in rodents. D'Amico and colleagues in Aging Cell (2022) explored joint and cartilage mitochondrial health in osteoarthritis models. Early, preclinical research is also exploring skin, gut, brain, and heart pathways — but these are animal and cell findings, not human proof.

The evidence for fisetin

Fisetin's momentum comes largely from preclinical work. The most cited study, from a Mayo Clinic-led team published in eBioMedicine (2018), reported that fisetin reduced senescent cell burden and extended health and lifespan in aged mice — a striking result, but an animal result. Much of what makes fisetin exciting, including its senolytic and anti-inflammatory activity, has been established in cell and rodent models. Human trials are underway, including clinical work exploring senescence-related endpoints, but as of now the robust, published human efficacy data are more limited than what exists for urolithin A's muscle and mitochondrial endpoints. If you want a fuller primer, our what is fisetin explainer goes deeper.

This is not a knock on fisetin — senolytics are one of the most interesting frontiers in aging biology. It simply means the two compounds sit at different stages of the evidence pipeline: urolithin A has more human randomized data behind specific, measurable outcomes, while fisetin's strongest support today is preclinical.

Are they complementary?

Conceptually, yes. Mitophagy (urolithin A) and senolytic activity (fisetin) address different failure modes of aging tissue and do not obviously overlap or cancel out. Some people interested in a broad cellular-maintenance approach use them together, often on different schedules — for example, a daily mitochondrial-support routine alongside a periodic senolytic approach, since some senolytic protocols are studied as intermittent rather than daily. That said, there is no large human trial testing the specific combination, so combining them is a reasonable-sounding strategy rather than a proven one. If you take medications or have a health condition, talk with your doctor before stacking supplements; this is general education, not a treatment plan, and neither compound is a treatment for any disease — see your doctor for medical concerns.

How to choose by goal

Choose urolithin A if your priority is energy, muscle, and mitochondria

If your main interest is cellular energy, muscle strength and endurance, exercise recovery, or supporting mitochondrial health as you age, urolithin A has the most directly relevant human data. It is also a straightforward daily supplement with a well-characterized safety profile in trials up to 1,000 mg per day. Our urolithin A benefits and urolithin A for energy pages break these outcomes down further.

Consider fisetin if your interest is senescent-cell biology

If you are specifically drawn to the senolytic angle — reducing the burden of aged, inflammatory cells — fisetin is the more relevant tool, with the caveat that you would be acting largely on preclinical evidence and early human work. Many people find the honest framing helpful: fisetin is promising and worth watching, but the human case is less mature.

When in doubt, start with the better-evidenced daily foundation

For most people building a longevity routine from scratch, a daily mitochondrial-support supplement with human data is a sensible foundation, with senolytics layered in later as the evidence matures. To go deeper on urolithin A specifically, see our complete urolithin A guide, compare formats and brands in our best urolithin A gummies roundup, and review the clinical studies in one place.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.